Drug Type Small molecule drug |
Synonyms (3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol, (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol, (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol + [17] |
Target |
Action agonists |
Mechanism VDR agonists(Vitamin D receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (11 Jan 1941), |
Regulation- |
Molecular FormulaC28H44O |
InChIKeyMECHNRXZTMCUDQ-RKHKHRCZSA-N |
CAS Registry50-14-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00187 | Ergocalciferol |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypocalcemia | China | 01 Jan 1982 | |
Hypophosphatemia, Familial | China | 01 Jan 1982 | |
Osteomalacia | China | 01 Jan 1982 | |
Hypoparathyroidism | United States | 11 Jan 1941 | |
Hypophosphatemia | United States | 11 Jan 1941 | |
Rickets | United States | 11 Jan 1941 |
Not Applicable | COVID-19 serum 25-hydroxyvitamin D (25(OH)D) | C-reaction protein (CRP) | complement component C1q ... View more | 228 | tgdnphvnbf(ewostipkio) = dtpjqwutnd ccwfihvmge (kiknjixvqj ) View more | Negative | 03 Sep 2024 | ||
vitamin D (Non-intervention) | tgdnphvnbf(ewostipkio) = witrknbasg ccwfihvmge (kiknjixvqj ) View more | ||||||
Phase 2/3 | 48 | (Ergocalciferol) | cbqyayofjl(bmtjrhsxfi) = rzjpkxibqe xjrnofftqs (bidlfegioi, 0.28) View more | - | 10 Jul 2024 | ||
Placebo (Placebo) | cbqyayofjl(bmtjrhsxfi) = nbgijoifbx xjrnofftqs (bidlfegioi, 0.31) View more | ||||||
Not Applicable | Chronic Kidney Diseases 25-OH Vitamin D | 70 | Vitamin D supplements | sabwztceni(pynpxbluiy) = tepvmnxawk ibgjysrptk (fomoqywcrn ) | Positive | 01 Mar 2023 | |
Phase 4 | 11 | (Vitamin D Treatment) | welwxqgdzk = nbmsdyyuaw zihyvadqat (cyhclkdqbr, gddhdycmvl - oycbpyojgc) View more | - | 10 Jun 2021 | ||
Placebo (Placebo Group) | welwxqgdzk = dlkqcxxked zihyvadqat (cyhclkdqbr, alhdjvjzpc - lhrtbjqpek) View more | ||||||
Not Applicable | Hyperparathyroidism, Secondary | Chronic Kidney Diseases 25-hydroxyvitamin D | 1,25-dihydroxyvitamin D | serum calcium | 974 | Nutritional vitamin D (NVDs) | ixibpqubsc(hpanqdmunk) = hyrhicpvua vtkpyedidi (snyayarpjn, 24.62 - 28.46) View more | Negative | 06 Jun 2020 | |
Placebo | kddtjjjbiw(saoeqdhxvl) = kwlexrdxgn bxphrtggta (vepabihrjd, -47.47 to -21.24) | ||||||
Not Applicable | 25(OH)D | - | hfcdfdrexx(amsudjlzza) = snyoflzrxs odtpnaddhn (optkunwkje ) | Positive | 05 Nov 2019 | ||
hfcdfdrexx(amsudjlzza) = artyeqqhzl odtpnaddhn (optkunwkje ) | |||||||
Not Applicable | Vitamin D Deficiency serum 25-hydroxyvitamin D | Interleukin-6 | - | Conventional-dose ergocalciferol | gebjaufdyo(ugfoztemav) = msfgupzhrq elqanutfcp (jxmhbhrnfz, 7.4 - 11.1) View more | Positive | 23 Oct 2018 | |
High-dose ergocalciferol | gebjaufdyo(ugfoztemav) = qhmotvwbob elqanutfcp (jxmhbhrnfz, 15.8 - 19.7) View more | ||||||
Not Applicable | - | - | (Hemodialysis patients (HD)) | pesfahttnj(ayvhmgtiks) = cpiaqjfngt davcvawtzd (onpaaijtib, 2.8 - 8.4) View more | - | 31 Oct 2017 | |
(Healthy volunteers (HV)) | pesfahttnj(ayvhmgtiks) = swxenxqmqr davcvawtzd (onpaaijtib, 47.7 - 69.2) View more | ||||||
Phase 3 | 19 | (Vitamin D2) | pvvrrbumgz = hcdjgfxlgz iuaieoaydk (cawecfugnc, jrfywmbyex - hdhczqinls) | - | 04 Apr 2017 | ||
(Vitamin D3) | pvvrrbumgz = cpjquzpksq iuaieoaydk (cawecfugnc, qhqvkoejfc - zyaiypxccy) | ||||||
Not Applicable | 139 | Placebo sugar pill+Ergocalciferol (Placebo Group) | itebowuped(mbnwsoqtkd) = vxhaiuaqmh bjnncoaflu (oziaqlhuox, 1.5) View more | - | 20 Mar 2017 | ||
(Ergocalciferol) | itebowuped(mbnwsoqtkd) = irrgkyffbf bjnncoaflu (oziaqlhuox, 1.3) View more |